|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Finkelstein DM, Ettinger DS and
Ruckdeschel JC: Long term survivors in metastatic non-small-cell
lung cancer: an Eastern Cooperative Oncology Group Study. J Clin
Oncol. 4:702–709. 1986.PubMed/NCBI
|
|
3
|
Slebos RJ, Kibbelaar RE, Dalesio O, et al:
K-ras oncogene activation as a prognostic marker in adenocarcinoma
of the lung. N Engl J Med. 323:561–565. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horio Y, Takahashi T, Kuroishi T, et al:
Prognostic significance of p53 mutations and 3p deletions in
primary resected non-small cell lung cancer. Cancer Res. 53:1–4.
1993.PubMed/NCBI
|
|
5
|
Makrantonakis PD, Galani E and Harper PG:
Non-small cell lung cancer in the elderly. Oncologist. 9:556–560.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maione P, Rossi A, Sacco PC, et al:
Treating advanced non-small cell lung cancer in the elderly. Ther
Adv Med Oncol. 2:251–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Owonikoko TK, Ragin CC, Belani CP, et al:
Lung cancer in elderly patients: an analysis of the surveillance,
epidemiology, and end results database. J Clin Oncol. 25:5570–5577.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brambilla E, Travis WD, Colby TV, et al:
The new World Health Organization classification of lung tumours.
Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar
|
|
10
|
Blanchon F, Grivaux M, Zureik M, et al:
Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in
lung cancer. Rev Mal Respir. 23:165–171. 2006.(In French).
|
|
11
|
Quoix E and Lemarié E: Epidemiological
novelties in lung cancer. Rev Mal Respir. 28:1048–1058. 2011.(In
French).
|
|
12
|
Hutchins LF, Unger JM, Crowley JJ, Coltman
CA Jr and Albain KS: Underrepresentation of patients 65 years of
age or older in cancer-treatment trials. N Engl J Med.
341:2061–2067. 1999.PubMed/NCBI
|
|
13
|
Lewis JH, Kilgore ML, Goldman DP, et al:
Participation of patients 65 years of age or older in cancer
clinical trials. J Clin Oncol. 21:1383–1389. 2003.PubMed/NCBI
|
|
14
|
Lichtman SM, Wildiers H, Chatelut E, et
al: International Society of Geriatric Oncology Chemotherapy
Taskforce: evaluation of chemotherapy in older patients - an
analysis of the medical literature. J Clin Oncol. 25:1832–1843.
2007. View Article : Google Scholar
|
|
15
|
Jatoi A, Hillman S, Stella P, et al:
Should elderly non-small-cell lung cancer patients be offered
elderly-specific trials? Results of a pooled analysis from the
north Central Cancer Treatment Group. J Clin Oncol. 23:9113–9119.
2005. View Article : Google Scholar
|
|
16
|
Perrone F, Gallo C and Gridelli C:
Cisplatin-based therapy for elderly patients with advanced
non-small cell lung cancer: implications of Eastern Cooperative
Oncology Group 5592, a randomized trial. J Natl Cancer Inst.
94:1029–1031. 2002. View Article : Google Scholar
|
|
17
|
Earle CC, Neumann PJ, Gelber RD, Weinstein
MC and Weeks JC: Impact of referral patterns on the use of
chemotherapy for lung cancer. J Clin Oncol. 20:1786–1792. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ries LAG, Eisner MP and Kosary CL: SEER
Cancer Statistics Review 1975–2000. National Cancer Institute;
Bethesda, MD: 2003, http://seer.cancer.gov/csr/1975_2000.
Accessed August 3, 2012
|
|
19
|
Earle CC, Tsai JS, Gelber RD, Weinstein
MC, Neumann PJ and Weeks JC: Effectiveness of chemotherapy for
advanced lung cancer in the elderly: instrumental variable and
propensity analysis. J Clin Oncol. 19:1064–1070. 2001.PubMed/NCBI
|
|
20
|
Langer CJ, Manola J, Bernardo P, et al:
Cisplatin-based therapy for elderly patients with advanced
non-small-cell lung cancer: implications of Eastern Cooperative
Oncology Group 5592, a randomized trial. J Natl Cancer Inst.
94:173–181. 2002. View Article : Google Scholar
|
|
21
|
Langer CJ, Vangel M and Schiller J:
Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80
yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc
Clin Oncol. 22:6392003.
|
|
22
|
Lilenbaum RC, Herndon JE II, List MA, et
al: Single-agent versus combination chemotherapy in advanced
non-small-cell lung cancer: the cancer and leukemia group B (study
9730). J Clin Oncol. 23:190–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Belani CP and Fossella FV: Phase III study
(TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus
vinorelbine-cisplatin for the first-line treatment of
advanced/metastatic non-small cell lung cancer: analyses in elderly
patients. Lung Cancer. 41(Suppl 2): S182003. View Article : Google Scholar
|
|
24
|
Ansari RH, Socinski MA, Edelman MJ, et al:
A retrospective analysis of outcomes by age in a three-arm phase
III trial of gemcitabine in combination with carboplatin or
paclitaxel vs. paclitaxel plus carboplatin for advanced non-small
cell lung cancer. Crit Rev Oncol Hematol. 78:162–171. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelly K, Crowley J, Bunn PA Jr, et al:
Randomized phase III trial of paclitaxel plus carboplatin versus
vinorelbine plus cisplatin in the treatment of patients with
advanced non-small-cell lung cancer: a Southwest Oncology Group
trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
|
|
26
|
Ramsey SD, Moinpour CM, Lovato LC, et al:
Economic analysis of vinorelbine plus cisplatin versus paclitaxel
plus carboplatin for advanced non-small-cell lung cancer. J Natl
Cancer Inst. 94:291–297. 2002. View Article : Google Scholar
|
|
27
|
Kelly K, Giarritta S and Hayes S: Should
older patients receive combination chemotherapy for advanced stage
non-small cell lung cancer? An analysis of Southwest Oncology
trials 9509 and 9308. Proc Am Soc Clin Oncol. 20:3292001.
|
|
28
|
No authors listed. Effects of vinorelbine
on quality of life and survival of elderly patients with advanced
non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine
Italian Study Group. J Natl Cancer Inst. 91:66–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frasci G, Lorusso V, Panza N, et al:
Gemcitabine plus vinorelbine yields better survival outcome than
vinorelbine alone in elderly patients with advanced non-small cell
lung cancer. A Southern Italy Cooperative Oncology Group (SICOG)
phase III trial. Lung Cancer. 34(Suppl 4): S65–S69. 2001.
View Article : Google Scholar
|
|
30
|
Gridelli C, Perrone F, Gallo C, et al:
Chemotherapy for elderly patients with advanced non-small-cell lung
cancer: the Multicenter Italian Lung cancer in the Elderly Study
(MILES) phase III randomized trial. J Natl Cancer Inst. 95:362–372.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gridelli C, Aapro M, Ardizzoni A, et al:
Treatment of advanced non-small-cell lung cancer in the elderly:
results of an international expert panel. J Clin Oncol.
23:3125–3137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kudoh S, Takeda K, Nakagawa K, et al:
Phase III study of docetaxel compared with vinorelbine in elderly
patients with advanced non-small-cell lung cancer: results of the
West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin
Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Depierre A, Chastang C, Quoix E, et al:
Vinorelbine versus vinorelbine plus cisplatin in advanced non-small
cell lung cancer: a randomized trial. Ann Oncol. 5:37–42.
1994.PubMed/NCBI
|
|
34
|
Anderson H, Hopwood P, Stephens RJ, et al:
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable
non-small cell lung cancer - a randomized trial with quality of
life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small
Cell Lung Cancer. Br J Cancer. 83:447–453. 2000.PubMed/NCBI
|
|
35
|
Roszkowski K, Pluzanska A, Krzakowski M,
et al: A multicenter, randomized, phase III study of docetaxel plus
best supportive care versus best supportive care in
chemotherapy-naive patients with metastatic or non-resectable
localized non-small cell lung cancer (NSCLC). Lung Cancer.
27:145–157. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Le Chevalier T, Brisgand D, Douillard JY,
et al: Randomized study of vinorelbine and cisplatin versus
vindesine and cisplatin versus vinorelbine alone in advanced
non-small-cell lung cancer: results of a European multicenter trial
including 612 patients. J Clin Oncol. 12:360–367. 1994.PubMed/NCBI
|
|
37
|
No authors listed. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. Non-small
Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sandler AB, Nemunaitis J, Denham C, et al:
Phase III trial of gemcitabine plus cisplatin versus cisplatin
alone in patients with locally advanced or metastatic
non-small-cell lung cancer. J Clin Oncol. 18:122–130.
2000.PubMed/NCBI
|
|
39
|
Crinò L, Scagliotti G, Marangolo M, et al:
Cisplatin-gemcitabine combination in advanced non-small-cell lung
cancer: a phase II study. J Clin Oncol. 15:297–303. 1997.
|
|
40
|
Azzoli CG, Giaccone G, Temin S, et al:
American Society of Clinical Oncology Clinical Practice Guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
|
|
41
|
Pallis AG, Gridelli C, van Meerbeeck J, et
al: EORTC Elderly Task Force and Lung Cancer Group and
International Society for Geriatric Oncology (SIOG) experts’
opinion for the treatment of non-small-cell lung cancer in an
elderly population. Ann Oncol. 21:692–706. 2010.
|
|
42
|
Weiss GJ, Langer C, Rosell R, et al:
Elderly patients benefit from second-line cytotoxic chemotherapy: a
subset analysis of a randomized phase III trial of pemetrexed
compared with docetaxel in patients with previously treated
advanced non-small-cell lung cancer. J Clin Oncol. 24:4405–4411.
2006. View Article : Google Scholar
|
|
43
|
Balducci L, Hardy CL and Lyman GH:
Hemopoietic reserve in the older cancer patient: clinical and
economic considerations. Cancer Control. 7:539–547. 2000.PubMed/NCBI
|
|
44
|
Balducci L: Geriatric oncology: challenge
for the new century. Eur J Cancer. 36:1741–1754. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Repetto L, Venturino A, Fratino L, et al:
Geriatric oncology: a clinical approach to the older patient with
cancer. Eur J Cancer. 39:870–880. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wijermans P, Lübbert M, Verhoef G, et al:
Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for
the treatment of high-risk myelodysplastic syndrome: a multicenter
phase II study in elderly patients. J Clin Oncol. 18:956–962.
2000.
|
|
47
|
Repetto L, Biganzoli L, Koehne CH, et al:
EORTC Cancer in the Elderly Task Force guidelines for the use of
colony-stimulating factors in elderly patients with cancer. Eur J
Cancer. 39:2264–2272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Repetto L, Venturino A, Vercelli M, et al:
Performance status and comorbidity in elderly cancer patients
compared with young patients with neoplasia and elderly patients
without neoplastic conditions. Cancer. 82:760–765. 1998. View Article : Google Scholar
|
|
49
|
Aldoss IT, Tashi T, Gonsalves W, et al:
Role of chemotherapy in the very elderly patients with metastatic
pancreatic cancer - a Veterans Affairs Cancer Registry analysis. J
Geriatr Oncol. 2:209–214. 2011. View Article : Google Scholar
|
|
50
|
Extermann M and Hurria A: Comprehensive
geriatric assessment for older patients with cancer. J Clin Oncol.
25:1824–1831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ferrucci L, Guralnik JM, Cavazzini C,
Bandinelli S, et al: The frailty syndrome: a critical issue in
geriatric oncology. Crit Rev Oncol Hematol. 46:127–137. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Repetto L, Fratino L, Audisio RA, et al:
Comprehensive geriatric assessment adds information to Eastern
Cooperative Oncology Group performance status in elderly cancer
patients: an Italian Group for Geriatric Oncology Study. J Clin
Oncol. 20:494–502. 2002. View Article : Google Scholar
|
